Both! The mixing of AZ with Sputnik is, rightly, the subject of a new trial.
-
-
Replying to @ArisKatzourakis
This may not have enough data because it is presented as an alternative to not offering any booster at all so may not have a sample size with power. Do you think it should be trialed anyway? Seems like something to avoid except as desperate measure? (Agree they should track).
2 replies 0 retweets 0 likes -
Replying to @zeynep
It seems doubly worrying in some ways if it will be deployed on edge cases that are unlikely to return. Hence there will be no data collected on this.
1 reply 0 retweets 1 like -
Replying to @ArisKatzourakis
Yes they should track if they do it, even rarely. That said, they had a real trial planned on this. (Not because of supply—to see if it was better.) I’ll track down what happened. That’s what I was wondering, why is there an expectation it might be better?https://www.theguardian.com/world/2020/dec/08/covid-mixed-vaccine-trial-likely-to-begin-in-uk-next-month …
2 replies 0 retweets 2 likes -
Replying to @zeynep @ArisKatzourakis
In early December, the UK task force said that it was going to trial various combinations to see if it induced heterologous prime-boost. (Again different than last-resort scenario in guidelines). I was just wondering if you think that’s a high priority for a trial?
0 replies 0 retweets 2 likes -
This Tweet is unavailable.
-
Replying to @andrew_croxford @ArisKatzourakis
That’s what I’m trying to understand. Is there an immunological reason to expect a significant upside? Or is it a supply chain or logistics issue because non-mRNA vaccines are bottlenecked? Poor countries aren’t getting much anytime soon plus their cold-chain is hard.
0 replies 0 retweets 4 likes -
This Tweet is unavailable.
-
This Tweet is unavailable.
-
Replying to @andrew_croxford @ArisKatzourakis
Yep, we are looking at a scenario where billions of people will potentially be denied vaccination in 2021—or be offered much less efficacious ones compared with wealthy countries. Hence the many questions. Supply and money is one problem, tough cold chain requirements is another.
1 reply 0 retweets 2 likes
Much of the 2021 supply of the very high efficacy two-dose vaccines has been purchased by wealthy countries. So it’s either increase supply or find other combinations that work as well (I don’t know if the latter is likely or possible hence the questions).
-
-
Replying to @zeynep @andrew_croxford
This is key, both in terms of fairness and global outcomes, but also I would argue for minimising the chance of vaccine escape arising.
0 replies 0 retweets 1 likeThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.